Edgewise Therapeutics (EWTX)
(Real Time Quote from BATS)
$13.64 USD
+0.03 (0.22%)
Updated Aug 5, 2025 11:36 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EWTX 13.64 +0.03(0.22%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Other News for EWTX
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
Raymond James Initiates Coverage on Edgewise Therapeutics (EWTX) with Strong Buy
Edgewise Therapeutics initiated with bullish view at Raymond James, here's why
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc